Ibnsina Pharma (EGX:ISPH)

Market Cap	12.61B +36.0%
Revenue (ttm)	80.05B +28.5%
Net Income	831.09M +46.9%
EPS	0.82 +46.9%
Shares Out	1.01B
PE Ratio	15.17
Forward PE	10.34
Dividend	0.16 (1.28%)
Ex-Dividend Date	Apr 27, 2026

Volume	25,846,030
Open	12.15
Previous Close	12.15
Day's Range	12.22 - 12.71
52-Week Range	8.17 - 13.72
Beta	0.69
Analysts	Strong Buy
Price Target	17.26 (+37.97%)
Earnings Date	Aug 13, 2026

About Ibnsina Pharma

Ibnsina Pharma operates as a pharmaceutical distributor in Egypt. The company offers pharmaceutical and cosmetics products to private and public-sector customers, including retail chains, independent pharmacies, wholesalers, hospitals, and healthcare institutions. It also provides warehousing and logistics services for its suppliers; marketing solutions; importation and packaging services; and market research and analysis services, as well as telesales and promotion services. The company was founded in 2001 and is headquartered in El Obour City...

• Industry: Drugs, Drug Proprietaries, and Druggists' Sundries
• Founded: 2001
• Employees: 5,500
• Stock Exchange: Egyptian Stock Exchange
• Ticker Symbol: ISPH

Financial Performance

In 2025, Ibnsina Pharma's revenue was 76.60 billion, an increase of 37.17% compared to the previous year's 55.84 billion. Earnings were 771.11 million, an increase of 54.90%.

Analyst Summary

According to 3 analysts, the average rating for ISPH stock is "Strong Buy." The 12-month stock price target is E£17.26, which is an increase of 37.97% from the latest price.

Price Target

E£17.26

(37.97% upside)

Analyst Consensus: Strong Buy